The aim of this study is to evaluate the effects of three-month course of treatment modalities (Cyproterone compound-Spironolactone, Metformin and Pioglitazone) in patients with polycystic ovary syndrome (PCOS) on markers of inflammation \[serum complement, homocysteine and high sensitive C-reactive protein (hs-CRP)\] levels.
No linked publications found in PubMed
Inclusion Criteria: * Age 18-35 years * Diagnosis of Polycystic Ovary Syndrome (PCOS) according to Rotterdam criteria 2003 (two out of three required): 1. Oligomenorrhea or anovulation 2. Clinical and/or biochemical signs of hyperandrogenism 3. Polycystic ovaries (by ultrasound) Exclusion Criteria: * Smoking * Pregnancy * Diabetes mellitus * Renal failure (serum creatinine \>1.5) * Congenital adrenal hyperplasia * Hyper or hypothyroidism * Sex hormone therapy or antiandrogen therapy during the last three months * Unexplained serum alanin aminotransferase (ALT) elevation more than 2.5 times above normal range * Any systemic or febrile illnesses * Use of glucocorticoid or anti-inflammatory drugs during the last three months * Androgen secreting tumor * Malignancy